Egypt vs Kiribati: Death rate from cancer
Egypt
82.54 deaths per 100,000 people
in 2021
Kiribati
85.23 deaths per 100,000 people
in 2021
Egypt rank
107th
Kiribati rank
104th
Death rate from cancer over time
- Egypt
- Kiribati
How they compare
Kiribati currently reports 85.23 deaths per 100,000 people against 82.54 deaths per 100,000 people in Egypt, a difference of 2.69 deaths per 100,000 people.
The two have swapped places 1 time across 22 shared years of data; in 2000 it was Egypt ahead.
Egypt ranks 107th and Kiribati ranks 104th of 194 countries.
Egypt has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Egypt | Kiribati | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 74.12 deaths per 100,000 people | 66.43 deaths per 100,000 people | 7.7 deaths per 100,000 people | Egypt |
| 2010s | 80.88 deaths per 100,000 people | 70.47 deaths per 100,000 people | 10.41 deaths per 100,000 people | Egypt |
| 2020s | 81.38 deaths per 100,000 people | 80.64 deaths per 100,000 people | 0.735 deaths per 100,000 people | Egypt |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher death rate from cancer, Egypt or Kiribati?
- Kiribati, at 85.23 deaths per 100,000 people against 82.54 deaths per 100,000 people in Egypt as of 2021.
- What is the difference in death rate from cancer between Egypt and Kiribati?
- 2.69 deaths per 100,000 people, with Kiribati ahead.
- How many years of comparable data are there for Egypt and Kiribati?
- 22 years are reported by both, from 2000 to 2021.
- How do Egypt and Kiribati rank globally for death rate from cancer?
- Egypt ranks 107th and Kiribati ranks 104th of 194 countries.
- Where does this data come from?
- World Health Organization (2024) – with major processing by Our World in Data, published as Death rate from cancer. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated number of deaths from malignant neoplasms in both sexes, per 100,000 people.